This presentation was recorded live at the 2016 IVC and Chronic Illness Symposium hosted by the Riordan Clinic. To find out more about the Riordan Clinic visit https://riordanclinic.org/ Son of Dr. Hugh Riordan, the founder of Medistem, will explain how mesenchymal stem cells and the molecular products that they produce are the key to not only maintaining health but successfully recovering from severe “untreatable” chronic illnesses.
Categories
Stem cell trial, OPC1
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
https://clinicaltrials.gov/ct2/show/NCT02302157?term=OPC1&rank=1
Ira Pastor, ideaXme exponential health ambassador and founder of Bioquark, interviews Dr Wise Young M.D., Ph.D., the Richard H. Shindell Chair in Neuroscience, Distinguished Professor of Cell Biology & Neuroscience and the Founding Director of the W. M. Keck Center for Collaborative Neuroscience at Rutgers University.
Alliance for Regenerative Medicine (ARM) Neuralstem Presentation
April 17, 2018
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. The company’s lead asset and stem cell therapy candidate, NSI-566, is a spinal cord-derived neural stem cell line being tested in Amyotrophic Lateral Sclerosis (ALS), chronic spinal cord injury (cSCI) and ischemic stroke. Additionally, NSI-189, is a chemical entity in development for major depressive disorder (MDD) and for Angelman syndrome, irradiation-induced cognitive impairment, neuropathy associated with Type 1 and Type 2 diabetes and stroke. These product candidates are based on the company’s proprietary neural stem cell technology. http://www.neuralstem.com
Categories
Chondroitinase
On August 28 Elon Musk gave us a one year update on his groundbreaking neural implant technology.